104 related articles for article (PubMed ID: 7791697)
1. [Rheumatology update--II. Overview of the clinically important status of knowledge and prospects for possible relevant trends in etiopathogenetic research, diagnostic methods and therapeutic possibilities].
Hein G; Bolwin R; Bräuer R; Eidner T; Franke S; Oelzner P; Sprott H
Med Klin (Munich); 1995 May; 90(5):294-302. PubMed ID: 7791697
[No Abstract] [Full Text] [Related]
2. [Rheumatology update--II. Summary of clinically significant current knowledge and outlook of prospective relevant trends in etiopathogenic research, diagnostic methods and therapeutic possibilities].
Hein G; Bolwin R; Bräuer R; Eidner T; Franke S; Oelzner P; Sprott H
Med Klin (Munich); 1996 Apr; 91 Suppl 1():56-64. PubMed ID: 8657087
[No Abstract] [Full Text] [Related]
3. [Rheumatology update--I. Summary of clinically significant current knowledge and outlook of possible relevant trends in etiopathogenic research, diagnostic methods and therapeutic possibilities].
Hein G; Bolwin R; Bräuer R; Eidner T; Franke S; Oelzner P; Sprott H
Med Klin (Munich); 1996 Apr; 91 Suppl 1():47-55. PubMed ID: 8657086
[No Abstract] [Full Text] [Related]
4. [Rheumatology update--1. Summary of clinically significant current knowledge and outlook perspective of relevant trends in etiopathogenetic research, diagnostic methods and therapeutic possibilities].
Hein G; Bolwin R; Bräuer R; Eidner T; Franke S; Oelzner P; Sprott H
Med Klin (Munich); 1995 Apr; 90(4):231-9. PubMed ID: 7776937
[No Abstract] [Full Text] [Related]
5. Current immunotherapy in rheumatoid arthritis.
Meier FM; Frerix M; Hermann W; Müller-Ladner U
Immunotherapy; 2013 Sep; 5(9):955-74. PubMed ID: 23998731
[TBL] [Abstract][Full Text] [Related]
6. [Experimental therapy of rheumatoid arthritis with cytokine antagonists].
Manger B
Z Rheumatol; 1995; 54(2):105-9. PubMed ID: 7793156
[TBL] [Abstract][Full Text] [Related]
7. Immunological therapies for rheumatoid arthritis.
Edwards CJ
Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials.
Gerlag DM; Tak PP
Best Pract Res Clin Rheumatol; 2008 Apr; 22(2):311-23. PubMed ID: 18455687
[TBL] [Abstract][Full Text] [Related]
9. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.
Feldmann M; Brennan FM; Williams RO; Woody JN; Maini RN
Best Pract Res Clin Rheumatol; 2004 Feb; 18(1):59-80. PubMed ID: 15123038
[TBL] [Abstract][Full Text] [Related]
10. Correlation between the immunophenotypical presentation of dendritic cells and the clinical response to anti-rheumatic treatment in rheumatoid arthritis.
Bălănescu A; Nat R; Regalia T; Radu E; Bojincă V; Ionescu R; Predescu V; Popescu E; Predeţeanu D
Rom J Intern Med; 2003; 41(3):255-67. PubMed ID: 15526509
[TBL] [Abstract][Full Text] [Related]
11. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker.
Wijbrandts CA; Vergunst CE; Haringman JJ; Gerlag DM; Smeets TJ; Tak PP
Arthritis Rheum; 2007 Nov; 56(11):3869-71. PubMed ID: 17968928
[No Abstract] [Full Text] [Related]
12. Expanding role of biologic agents in rheumatoid arthritis.
Kalden JR
J Rheumatol Suppl; 2002 Nov; 66():27-37. PubMed ID: 12435166
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
14. Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera.
Matsuno H; Yudoh K; Nakazawa F; Sawai T; Uzuki M; Nishioka K; Yonehara S; Nakayama J; Ohtsuki M; Kimura T
J Rheumatol; 2002 Aug; 29(8):1609-14. PubMed ID: 12180717
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.
Haraoui B
J Rheumatol Suppl; 2005 Jan; 72():46-7. PubMed ID: 15660467
[TBL] [Abstract][Full Text] [Related]
16. Initial experience combining methotrexate with biologic agents for treating rheumatoid arthritis.
Moreland LW
J Rheumatol Suppl; 1996 Mar; 44():78-83. PubMed ID: 8833060
[TBL] [Abstract][Full Text] [Related]
17. [Rheumatology 2007].
Feist E; Burmester GR
Dtsch Med Wochenschr; 2007 Jun; 132(25-26):1396-8. PubMed ID: 17570088
[No Abstract] [Full Text] [Related]
18. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years).
Luqmani R; Hennell S; Estrach C; Basher D; Birrell F; Bosworth A; Burke F; Callaghan C; Candal-Couto J; Fokke C; Goodson N; Homer D; Jackman J; Jeffreson P; Oliver S; Reed M; Sanz L; Stableford Z; Taylor P; Todd N; Warburton L; Washbrook C; Wilkinson M; ;
Rheumatology (Oxford); 2009 Apr; 48(4):436-9. PubMed ID: 19174570
[No Abstract] [Full Text] [Related]
19. Practical aspects of therapeutic intervention in rheumatoid arthritis.
Thompson A
J Rheumatol Suppl; 2009 Jun; 82():39-41. PubMed ID: 19509329
[TBL] [Abstract][Full Text] [Related]
20. What is after cytokine-blocking therapy, a novel therapeutic target--synovial Epstein-Barr virus for rheumatoid arthritis.
Sawada S; Takei M; Inomata H; Nozaki T; Shiraiwa H
Autoimmun Rev; 2007 Jan; 6(3):126-30. PubMed ID: 17289546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
